Alkem reports ₹675 crore PAT as biotech sales fall 37%
In short
Alkem Laboratories reported a profit after tax of ₹675 crore. Its biotech sales fell 37%, while total revenue from operations rose 13.8% to ₹4,552 crore.
The company said the biotech weakness was linked to lumpy CDMO business. Investors will read the numbers for signs of how the different divisions are performing.
What the reporting says
Alkem Laboratories posted profit after tax of ₹675 crore, while biotech sales fell 37% in the period, hit by what was described as lumpy CDMO business. The company’s total revenue from operations came in at ₹4,552 crore, up 13.8% from the same period last year. The results point to mixed performance across the business lines.
Why it matters
Alkem Laboratories posted profit after tax of ₹675 crore, while biotech sales dropped 37% in the reported period. The company’s total revenue from operations rose 13.8% year on year to ₹4,552 crore, showing stronger top-line growth even as biotech underperformed. The update highlights mixed results for investors tracking the pharma company’s business segments.